Latest Articles

Publication Date
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Sonographic and Clinical Progression of Adenomyosis and Coexisting Endometriosis: Long-Term Insights and Management Perspectives.

Objectives: To evaluate the impact of hormonal therapy on the evolution of painful symptoms in premenopausal women with adenomyosis, with or without concomitant endometriosis, over an 18-month follow-up period. This …

Published: Nov. 6, 2025, midnight
Nanodrug impact on female reproductive health and fetal development: From translation approaches to long-term safety concern.

Biomaterials for drug delivery offer significant advantages over conventional medications, including enhanced cellular uptake, improved drug stability, targeted delivery, and controlled drug release. Cutting-edge nanodrugs delivery approaches such as drugs …

Published: Nov. 5, 2025, midnight
Catamenial pneumothorax with histologically proven diaphragmatic endometriosis successfully managed by combined surgical resection and hormonal therapy: A four-year recurrence-free case.

Catamenial pneumothorax (CP) is a rare form of spontaneous pneumothorax associated with thoracic endometriosis. We report a case of CP with histologically proven diaphragmatic endometriosis successfully managed by combined surgical …

Published: Nov. 5, 2025, midnight
Psychoneuroendocrine Associations with Momentary Pelvic Pain in Endometriosis.

Endometriosis is a gynecological condition which often causes chronic or recurrent pelvic pain (CPP). The disease can thereby impose a significant burden on affected individuals and their romantic relationships. Existing …

Published: Nov. 4, 2025, midnight
Psychosocial Factors and Disease Localization as Independent Predictors of Sexual Dysfunction in Women with Endometriosis.

Background: This study examines the impact of endometriosis on sexual function, focusing on disease localization, pain severity, and psychosocial factors. It integrates the rASRM and Enzian classification systems to explore …

Published: Nov. 2, 2025, midnight
Effect of kisspeptin, neurokinin, and dynorphin neurons on regulation of reproduction.

Gonadotropin-releasing hormone pulsatility is under the influence of hypothalamic neuropeptides, especially neurons expressing kisspeptin, neurokinin B, and dynorphin. These hypothalamic cells are called KNDy neurons. By integrating hormonal and environmental …

Published: Nov. 1, 2025, midnight
Lactate-mediated immune suppression and MDSC expansion in endometriosis: Mechanisms and nanoparticle-targeted therapies.

Endometriosis, a chronic gynecological disorder characterized by the ectopic growth of endometrial-like tissue, is associated with severe pelvic pain, infertility, and profound immune dysregulation. Despite advances in hormonal therapy and …

Published: Nov. 1, 2025, midnight
Integrative microbiome-metabolomics identifies Pseudomonas as a potential pathogenic factor in endometriosis.

Endometriosis (EMS) is a chronic disease characterized by unclear etiology, influenced by various genetic and environmental factors, with no definitive biomarkers available for early screening. Recent studies suggest that the …

Published: Oct. 30, 2025, midnight
Anti-Angiogenic RNAi-Based Treatment of Endometriosis in a Rat Model Using CXCR4-Targeted Peptide Nanoparticles.

Endometriosis is a common gynecological condition that affects fertility in many women of reproductive age worldwide. This multifaceted disease exhibits a pathogenesis characterized by hormonal and immune system dysregulations, alongside …

Published: Oct. 30, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!